Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Issue 8 (31st May 2017)

• Record Type: Journal Article
• Authors: Su, Shirley Y.; Bell, Diana; Ferrarotto, Renata; Phan, Jack; Roberts, Dianna; Kupferman, Michael E.; Frank, Steven J.; Fuller, C. David; Gunn, G. Brandon; Kies, Merrill S.; Glisson, Bonnie S.; Hanna, Ehab Y.
• Is Part Of: Head & neck. Volume 39:Issue 8(2017)
• Page Start: 1671
• Page End: 1679
• Publication Date: 2017-05-31
• Subjects: chemotherapy -- induction chemotherapy -- olfactory neuroblastoma -- orbital preservation -- skull base; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.24822
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Oncologic outcomes for induction chemotherapy and its role in patients with advanced olfactory neuroblastoma (ONB) remain unclear. Methods: A retrospective review of 15 consecutive patients with extensive local invasion and/or nodal disease treated with induction chemotherapy with curative intent followed by definitive local therapy. Results: The majority of patients were treated with cisplatin and etoposide. The response to chemotherapy was 68% (10/15). Response was 78% (7/9) in the high Hyams high‐grade group and 50% (3/6) in the Hyams low‐grade group. Seven patients had complete response (CR) and 3 patients were able to avoid orbital exenteration. The 5‐year disease‐free survival (DFS) and overall survival (OS) were 71% and 78%, respectively, with a trend toward improved survival in patients with CR. Conclusion: ONB is a chemosensitive tumor and induction chemotherapy is an acceptable strategy for aggressive and locoregional advanced disease. Hyams grade may predict chemosensitivity and CR may be associated with improved survival.